Compare PLPC & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLPC | ORIC |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.1M | 1.1B |
| IPO Year | N/A | 2020 |
| Metric | PLPC | ORIC |
|---|---|---|
| Price | $224.64 | $10.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 70.4K | ★ 1.3M |
| Earning Date | 10-29-2025 | 11-13-2025 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 7.55 | N/A |
| Revenue | ★ $663,346,000.00 | N/A |
| Revenue This Year | $16.31 | N/A |
| Revenue Next Year | $13.74 | N/A |
| P/E Ratio | $29.91 | ★ N/A |
| Revenue Growth | ★ 15.93 | N/A |
| 52 Week Low | $118.99 | $3.90 |
| 52 Week High | $245.99 | $14.93 |
| Indicator | PLPC | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 65.56 | 32.51 |
| Support Level | $200.62 | $10.45 |
| Resistance Level | $219.99 | $12.50 |
| Average True Range (ATR) | 7.74 | 0.82 |
| MACD | 3.15 | -0.13 |
| Stochastic Oscillator | 98.50 | 6.40 |
Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. In addition, it provides solar hardware systems and mounting hardware for a variety of solar power applications. Its products consist of Energy Products, Communications Products, and Special Industries Products. The company's majority of the revenue is derived from the sale of products in The Americas with operations also in PLP-USA, Europe, the Middle East and Africa, and Asia-Pacific. The revenue gets driven by Energy products which comprise protecting transmission conductors, spacers, spacer-dampers, and Stockbridge dampers.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.